# Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation

> **NCT02669940** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 158 (actual)

## Conditions studied

- Chronic Hepatitis C
- Genotype 1

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02669940
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-15
- **Primary completion:** 2017-07-04
- **Final completion:** 2017-07-04
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02669940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02669940, "Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02669940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*